Current state of art management for vascular complications after liver transplantation

Vascular complications by compromising the blood flow to the allograft can have significant and sometimes life-threating consequences for the patient. High level of suspicion and aggressive utilization of diagnostic modalities can lead to early diagnosis and salvage of the allograft. This review will summarize the current trends in the management of vascular complications after liver transplantation. Current trends show an increase in the utilization of endovascular interventions initially to address vascular complications after liver transplantation. Operative repair still has its major role, especially if endovascular procedures fail

Liver transplantation for hepatocellular carcinoma: past, present and future

Hepatocellular carcinoma [HCC] represents one of the most common neoplasms worldwide. Liver trasnplantation [LT] is the treatment of choice for selected group of patients with HCC. LT is actually a consolidated therapeutic option for HCC because it cures both tumor and underlying cirrhosis. In 1996, the publication of a pivotal prospective study on less than 50 patients, transplanted for HCC under predefined criteria [single HCC < 5 cm or 3 HCC < 3 cm each], the so called [Milan criteria], showed a 4-year survival of 75%. However, the indication of LT for HCC treatment has evolved over recent years. The possibility of an extension of Milan criteria as indication for LT is already a debated issue. Living donor LT [LDLT] is an alternative option if waiting list is long and of fers the possibility of a LT after a short time. In this review, the current indications and results of liver transplantion for HCC have been dsicusssed

Current status of liver transplantation

Liver transplantation [LTx] is the treatment of choice for patients with end-stage liver disease [ESLD]. Improvement in outcomes [allograft and patient survival] has led to widespread use of LTx worldwide. However, new problems that include severe organ shortage, recurrence of primary disease, opportunistic infections, and development of de novo malignancies are the major problems further implementation of LTx